'Global fragility' is adding to the pressure on forwarders
As high-value, temperature-sensitive cargo, pharmaceutical shipments can be complex and it is crucial to meet ...
PG: STEADY YIELDGM: INVESTOR DAY UPDATEBA: IT'S BADXOM: MOMENTUMFWRD: EVENT-DRIVEN UPSIDEPEP: TRADING UPDATE OUTMAERSK: BOTTOM FISHING NO MOREDHL: IN THE DOCKHLAG: GREEN DEALXOM: GEOPOLITICAL RISK AND OIL REBOUND IMPACTZIM: END OF STRIKE HANGOVERCHRW: GAUGING UPSIDEBA: STRIKE RISKDSV: STAR OF THE WEEK
PG: STEADY YIELDGM: INVESTOR DAY UPDATEBA: IT'S BADXOM: MOMENTUMFWRD: EVENT-DRIVEN UPSIDEPEP: TRADING UPDATE OUTMAERSK: BOTTOM FISHING NO MOREDHL: IN THE DOCKHLAG: GREEN DEALXOM: GEOPOLITICAL RISK AND OIL REBOUND IMPACTZIM: END OF STRIKE HANGOVERCHRW: GAUGING UPSIDEBA: STRIKE RISKDSV: STAR OF THE WEEK
The vast amounts of investment and research that logistics companies are putting into the pharmaceutical shipment business could soon be at least partly defunct following the first approval of 3D-printed drugs. Developed by Aprecia, the approved drug is to help control epilepsy and the 3D print process allows for a new, easy-to-dissolve structure as well as individual dosage control. This allows personalised medicine to be easily manufactured, delivered and stored. Will all that pharma cold chain expertise be wasted? Time will tell.
Comment on this article